Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Daiichi Sankyo Kicks Off PII for DS-8201 in NSCLC
June 1, 2018
- Shionogi Grabs Rights to Hsiri’s Mycobacterial Disease Therapies
June 1, 2018
- Roxadustat Hits Primary Endpoint in Japan PIII: Astellas/FibroGen
June 1, 2018
- FDA Accepts Eisai’s Fycompa for Pediatric Indication Review
June 1, 2018
- Astellas Files Japan NDA for JAK Inhibitor Peficitinib in RA
June 1, 2018
- Kissei’s Spinocerebellar Ataxia Treatment Fails to Hit Primary Targets in Japan PIII Study
June 1, 2018
- 3 Japan Drug Makers Launch Industry-Academia Consortium on Drug Discovery for Immune-Mediated Inflammatory Diseases
June 1, 2018
- Takeda Licenses Relugolix to ASKA in Women’s Health Field
June 1, 2018
- Perspective on Takeda/Shire Deal - 3: Takeda Shareholders Got Short End of the Stick
May 31, 2018
- Japan’s 1st Enbrel Biosimilar Makes Its Debut
May 31, 2018
- FDA Action Date for Mogamulizumab Extended for 3 Months: Kyowa Kirin
May 31, 2018
- Kowa to Launch Parmodia after Skipping 3 Listing Rounds
May 30, 2018
- Astellas’s Gilteritinib Gets FDA Priority Status
May 30, 2018
- Perspective on Takeda/Shire Deal - 2: Acquisition Might Mint More Investment Opportunities, Positive or Negative Not Yet Clear
May 30, 2018
- Chugai Files Actemra for Cytokine Release Syndrome
May 30, 2018
- Janssen Japan Chief Calls for Appropriate Rewards for Innovative Drugs
May 29, 2018
- Perspective on Takeda/Shire Deal - 1: Profits Delivered by On-Market Products More Important than Pipeline
May 29, 2018
- Pfizer Submits New Drug Application in Japan for Dacomitinib
May 29, 2018
- MSD Launches Prevymis for Prevention of CMV Infection
May 29, 2018
- JCR to Start PII Study of Hunter Syndrome Treatment in Brazil in June
May 29, 2018
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…